<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>MSF Topic:</title>
    <link>http://hdl.handle.net/10144/12148</link>
    <description />
    <pubDate>Sat, 25 May 2013 17:59:52 GMT</pubDate>
    <dc:date>2013-05-25T17:59:52Z</dc:date>
    <item>
      <title>Liposomal amphotericin B as a treatment for human leishmaniasis</title>
      <link>http://hdl.handle.net/10144/255342</link>
      <description>Title: Liposomal amphotericin B as a treatment for human leishmaniasis
Authors: Balasegaram, Manica; Ritmeijer, Koert; Lima, Maria Angeles; Burza, Sakib; Ortiz Genovese, Gemma; Milani, Barbara; Gaspani, Sara; Potet, Julien; Chappuis, François</description>
      <pubDate>Tue, 11 Dec 2012 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10144/255342</guid>
      <dc:date>2012-12-11T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Burden of visceral leishmaniasis in villages of eastern gedaref state, Sudan: an exhaustive cross-sectional survey.</title>
      <link>http://hdl.handle.net/10144/255395</link>
      <description>Title: Burden of visceral leishmaniasis in villages of eastern gedaref state, Sudan: an exhaustive cross-sectional survey.
Authors: Mueller, Yolanda Kathrin; Nackers, Fabienne; Ahmed, Khalid A; Boelaert, Marleen; Djoumessi, Jean-Claude; Eltigani, Rahma; Gorashi, Himida Ali; Hammam, Omer; Ritmeijer, Koert; Salih, Niven; Worku, Dagemlidet; Etard, Jean-François; Chappuis, François
Abstract: Since December 2009, Médecins Sans Frontières has diagnosed and treated patients with visceral leishmaniasis (VL) in Tabarak Allah Hospital, eastern Gedaref State, one of the main endemic foci of VL in Sudan. A survey was conducted to estimate the VL incidence in villages around Tabarak Allah.</description>
      <pubDate>Thu, 01 Nov 2012 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10144/255395</guid>
      <dc:date>2012-11-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Sodium Stibogluconate (SSG) &amp; Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial</title>
      <link>http://hdl.handle.net/10144/242363</link>
      <description>Title: Sodium Stibogluconate (SSG) &amp; Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
Authors: Musa, Ahmed; Khalil, Eltahir; Hailu, Asrat; Olobo, Joseph; Balasegaram, Manica; Omollo, Raymond; Edwards, Tansy; Rashid, Juma; Mbui, Jane; Musa, Brima; Abuzaid, Abuzaid Abdalla; Ahmed, Osama; Fadlalla, Ahmed; El-Hassan, Ahmed; Mueller, Marius; Mucee, Geoffrey; Njoroge, Simon; Manduku, Veronica; Mutuma, Geoffrey; Apadet, Lilian; Lodenyo, Hudson; Mutea, Dedan; Kirigi, George; Yifru, Sisay; Mengistu, Getahun; Hurissa, Zewdu; Hailu, Workagegnehu; Weldegebreal, Teklu; Tafes, Hailemariam; Mekonnen, Yalemtsehay; Makonnen, Eyasu; Ndegwa, Serah; Sagaki, Patrick; Kimutai, Robert; Kesusu, Josephine; Owiti, Rhoda; Ellis, Sally; Wasunna, Monique
Abstract: Alternative treatments for visceral leishmaniasis (VL) are required in East Africa. Paromomycin sulphate (PM) has been shown to be efficacious for VL treatment in India.</description>
      <pubDate>Fri, 01 Jun 2012 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10144/242363</guid>
      <dc:date>2012-06-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Low castes have poor access to visceral leishmaniasis treatment in Bihar, India</title>
      <link>http://hdl.handle.net/10144/220992</link>
      <description>Title: Low castes have poor access to visceral leishmaniasis treatment in Bihar, India
Authors: Pascual Martínez, F; Picado, A; Roddy, P; Palma, P
Abstract: Objectives  Bihar, the poorest state in India, concentrates most of the visceral leishmaniasis (VL) cases in the country. A large proportion of the poor rural communities where VL is endemic are marginalized by their socio-economic status, intrinsically related to the caste system. In this study, we evaluated whether people from low socio-economic strata had difficulties accessing VL treatment in Bihar. As a secondary outcome, we evaluated whether people delaying their VL treatment had poorer clinical indicators at admission. Methods  Data on 2187 patients with VL treated by Médecins Sans Frontières (MSF) in Vaishali district from July 2007 to December 2008 were analysed. Patients who reported having onset of symptoms ≥8 weeks before admission were defined as 'late presenters'. Logistic regression models were used to evaluate whether low castes had higher risk to be 'late presenters' compared to the rest of castes and whether 'late presenters' had poorer indicators at admission (i.e. haemoglobin level, spleen size). Results  After adjusting for age, gender and distance to VL treatment facility, Mushars (the lowest caste in Bihar) had twice the odds to be 'late presenters' compared to the rest of castes (OR 2.05, 95% CI: 1.24-2.38). Subjects that had VL symptoms for ≥8 weeks had a larger spleen and lower haemoglobin level than those that were treated earlier. Conclusion  Low castes have poor access to VL treatment in Bihar, and late presenters have poorer clinical indicators at admission. These findings have implications at individual and community levels and should stimulate targeted VL control programmes to ensure that marginalized communities in Bihar are properly treated.</description>
      <pubDate>Mon, 05 Mar 2012 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">http://hdl.handle.net/10144/220992</guid>
      <dc:date>2012-03-05T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

